Nexalis Therapeutics Limited · ASX:NX1
Nexalis Therapeutics — InhaleRx — Corporate Update (March 2025)
19 slides from Nexalis Therapeutics's corporate update, Mar 13, 2025
Slide 1: Shareholder Town Hall Webinar Slides
14 March 2025 ASX Announcement SHAREHOLDER TOWN HALL WEBINAR SLIDES InhaleRx Ltd (ASX: IRX), (“InhaleRx”, “IRX” ‘or “the Company”) an Australian drug development company developing unique inhaled drug-device products to address unmet medical needs in the pain management and mental health sectors, at
Slide 2: About InhaleRx Limited (ASX: IRX)
About InhaleRx Limited (ASX: IRX) – www.inhalerx.com.au InhaleRx Limited is an Australian drug development company which is developing unique medicinal drug- device products to address unmet medical needs in pain management and mental health sectors. The overarching goal is to pursue U.S. FDA approv
Slide 3: Developing Tomorrow's Inhaled Therapies
Town Hall Meeting 13th March 2025 DEVELOPING TOMORROW’S INHALED THERAPIES
Slide 4: Disclaimer
InhaleRx Ltd 13th March 2025 DISCLAIMER This presentation contains summary information about InhaleRx Limited (“InhaleRx” or “IRX” or “Company”) and its activities current as at the date of this presentation. It should be read in conjunction with InhaleRx’ other periodic and continuous disclosure an
Slide 5: About InhaleRx
3 InhaleRx Ltd 13th March 2025 ABOUT INHALERX InhaleRx Limited (ASX: IRX) is a clinical stage biotechnology development company focused on developing innovative inhaled therapeutics to address unmet medical needs in pain management and mental health treatment. Two drug/device candidates IP Portfolio
Slide 6: Developing IRX-211 as a Therapeutic Agent
4 InhaleRx Ltd 13th March 2025 DEVELOPING IRX-211 AS A THERAPEUTIC AGENT IRX-211 will be a registered prescription-only medication to treat Breakthrough Cancer Pain (BTcP). Cancer Pain Management Market grew from $7.42 billion in 2023 to $7.86 billion in 2024 and is expected to continue growing at a
Slide 7: Planning to Commence IRX-211
InhaleRx Ltd 13th March 2025 PLANNING TO COMMENCE IRX-211 MILESTONE COMPLETE EXPECTED (QUARTER) Funding Secured Recut of trial design Tender Commenced Spec Work Commenced Component Sourcing HREC Approval for Ph2 trial Protocol Amendment with HREC Q2 Batch Manufacturing Q2 First Patient Screened Q3 F
Slide 8: Developing IRX-616a as a Therapeutic Agent
6 InhaleRx Ltd 13th March 2025 DEVELOPING IRX-616a AS A THERAPEUTIC AGENT IRX-616a will be a registered prescription-only medication to treat Panic Disorder. The market of anxiety disorders and depression treatments is estimated to be valued at 22.6b (USD). There is no competition in terms of inhale
Slide 9: Planning to Commence IRX-616a
InhaleRx Ltd 13th March 2025 PLANNING TO COMMENCE IRX-616a MILESTONE COMPLETE EXPECTED (QUARTER) Funding Secured Medical writing complete Tender Commenced Spec Work Commenced Component Sourcing Tender complete HREC Application Q2/Q3 HREC Approval Q3 Batch Manufacturing Complete Q3 First Patient Scre
Slide 10: Highlights & Summary
8 InhaleRx Ltd 13th March 2025 HIGHLIGHTS & SUMMARY Funding Partner Secured the company has access of up to unique and exciting $38m in funding to accelerate our clinical development plans. Slashed cash burn in the company by over 70% since January 2024. Management Team is limited to myself, Dr Rob
Slide 11: Thank You
THANK YOU Any Questions? Please contact me at: Darryl Davies darryl.davies@inhalerx.com.au
Slide 12: Developing Tomorrow's Inhaled Therapies
Town Hall Meeting 13th March 2025 DEVELOPING TOMORROW’S INHALED THERAPIES
Slide 13: IRX211 – Revolutionizing Breakthrough Cancer Pain Management
IRX211 – Revolutionizing Breakthrough Cancer Pain Management Breakthrough cancer pain (BTcP) lacks sufficient treatment options. Current therapies rely heavily on opioids, raising addiction concerns. O u r flag sh ip p rod u ct, IRX 211, in tro d uc es a no vel ap p ro ach to ad d ress this m ed ica
Slide 14: Non-Opioid Analgesics: The Competitive Edge
Non-Opioid Analgesics: The Competitive Edge Market Context IRX211 Advantage Key Benefits Vertex’ s suzetrigine has emerged as a notable Our solution delivers rapid pain relief IRX211 shows superior PK profiles with notable non-opioid analgesic. The landscape a unique mechanism. This creates enhanced
Slide 15: Perfect Titration: Precision Management
Perfect Titration: Precision Management Rapid Onset IRX 211 a sp ires to d eliver imm ed iate- o nset relief when BTcP Th is timing is cruc ia l fo r effec tive m an ag em ent. FPE Avoidance The formulation bypasses first-pass metabolism. This ensures higher ensures higher bioavailability and more p
Slide 16: IRX211: Compelling Phase 1 Results
IRX211: C om pelling Phase 1 Results Predictable Pharmacokinetics Safety Profile Pathway Forward Pharm acokinetics IRX211 showed excellent tolerability. These promising results establish a solid The clinical study demonstrated a reliable Adverse events were minimal and solid foundation. We are confi
Slide 17: IRX616: Transforming Panic Disorder Treatment
IRX616: TransformingPanic Disorder Treatment Non-Addictive Solution 1 Breaking dependence cycles in panic management Just-In-Time Relief 2 Immediate response when patients need it most Personalized Dosing 3 Flexible titration for individual patient needs IRX616 represents our expanded portfolio addr
Slide 18: Accelerated Clinical Development Strategy
Accelerated C linical D evelopm ent Strateg y Phase 1 and Phase 2 in rapid succession 1 Intention is to move from Phase 1 to Phase 2 rapidly to minimize 2 Data- Driven D ecisions Obtaining key PK data and guidance on maximum safe dose dropped into an already written phase 2 protocol. FD A Dialog ue
Slide 19: Thank You
THANK YOU any questions? inhaleRx